MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Atara Biotherapeutics, Inc. (NASDAQ: ATRA)*
Organization & Developments: Atara
Parents
Atara Biotherapeutics, Inc. (NASDAQ: ATRA)*
Children
*Developing inhibitor of activin, represents a novel targeted approach for the treatment of ovarian cancer as well as other solid tumors.
*Developing treatment for protein energy wasting (PEW), a form of inflammation, malnutrition and muscle wasting in patients with end-stage renal disease.
2018: Atara Biotherapeutics: Buy The Secondary - Atara Biotherapeutics (NASDAQ:ATRA)
2018: Reader Inquiry: What's The Outlook For Atara Biotherapeutics After The Recent Secondary?_seekingalpha.com
2019: Atara: Shifting Toward CAR-T_seekingalpha.com
2020: Atara: Sound Medicine, High Stock Price
2021: Revisiting Atara Biotherapeutics
2022: After a series of clinical stumbles, Atara lays off 20% of staff and slims R&D focus
2022: Atara Biotherapeutics: Early Stage Promises, Late Stage Delays_ seekingalpha.com
2022: Atara's stock plummets 55% following inconclusive phase 2 MS analysis
2022: Consider Atara Biotherapeutics As The Tab-Cel Delay Resolves In The U.S._ seekingalpha.com
2023: Atara's Balancing Act: Innovation On A Fiscal Tightrope_seekingalpha.com
2024: Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway
2025: Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues
2025: Atara, reeling from FDA hold on Ebvallo, lays off half of workforce
2025: Manufacturing Issues Result in FDA Rejection of Atara’s Cell Therapy
Nina Biotherapeutics, Inc.
Pinta Biotherapeutics, Inc.
Santa Maria Biotherapeutics, Inc
Jumps
*Key People: Atara
Finance & Acquisitions: Atara